EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Checkpoint Inhibitors (ICI) in Urological Cancers: A New Modern Era, but Not Generally Applied

Marcin Sokołowski iD, Anna Sokołowska, Magdalena Chrząszcz iD, Aleksandra Butrym iD

International Journal of Molecular Sciences · 25.07.2025 · 26 (15) · 7194

DOI: 10.3390/ijms26157194 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.07.2025. Verfasst von Marcin Sokołowski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dr Alfred Sokołowski Specialist Hospital in Walbrzych, 58-309 Walbrzych, Poland. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Urologic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The modern era of systemic treatment of urological cancers is definitely marked by checkpoint inhibitors. Over the past 30 years, checkpoint inhibitors have changed the oncological world, especially in chemoresistant malignancies. Multiple investigations focused on immunotherapy in urological cancers have carved new paradigms and changed clinical guidelines. However, some clinical trials have been blind alleys for systemic therapy. After a scrutinized review of electronic databases, we want to present the natural history and courses of clinical trials in urological malignancies. All of them contribute to expanding the knowledge and experience of clinicians, and some of them improve the prognosis and prolong the overall survival of oncological patients. In conclusion, checkpoint inhibitors open a new modern era in some urological cancers, but not overall. Future perspectives are focused on combination with targeted therapy and could be a new way forward in the systemic treatment of urological cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsUrologic NeoplasmsHumansImmunotherapyClinical Trials as Topic

Stichwörter der Autor:innen

checkpoint inhibitorsimmunotherapyurological cancers

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Dr Alfred Sokołowski Specialist Hospital in Walbrzych, 58-309 Walbrzych, Poland.
  • Lower Silesian Oncology, Pulmonology and Hematology Center, pl. Hirszfelda 12, 53-413 Wroclaw, Poland.
  • Department of Cancer Prevention and Therapy, Wroclaw Medical University, ul Borowska 2-13, 50-556 Wroclaw, Poland.

ORCID-Profile: Marcin Sokołowski, Magdalena Chrząszcz, Aleksandra Butrym

Förderung

  • Medical Research Agency

Zitieren

APA

Sokołowski, M., Sokołowska, A., Chrząszcz, M., & Butrym, A. (2025). Immune Checkpoint Inhibitors (ICI) in Urological Cancers: A New Modern Era, but Not Generally Applied. International Journal of Molecular Sciences, 26(15), 7194. https://doi.org/10.3390/ijms26157194

Vancouver

Sokołowski M, Sokołowska A, Chrząszcz M, Butrym A. Immune Checkpoint Inhibitors (ICI) in Urological Cancers: A New Modern Era, but Not Generally Applied. International Journal of Molecular Sciences. 2025;26(15):7194. doi:10.3390/ijms26157194

BibTeX
@article{Sokoowski2025,
  author = {Sokołowski, Marcin and Sokołowska, Anna and Chrząszcz, Magdalena and Butrym, Aleksandra},
  title = {Immune Checkpoint Inhibitors (ICI) in Urological Cancers: A New Modern Era, but Not Generally Applied},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {15},
  pages = {7194},
  doi = {10.3390/ijms26157194}
}
Kostenlos starten →